June 21, 2017
Drugmaker Mylan gets boost from unlikely source: coal
Mylan N.V. <MYL.O> is best known for producing EpiPen emergency allergy treatments and generic drugs.
Pharmaceuticals, Biotechnology and Life Sciences
Category: North America
June 21, 2017
U.S. Supreme Court ruling threatens masive talc litigation against J&J
Johnson & Johnson is seizing upon a U.S. Supreme Court ruling from Monday limiting where injury lawsuits can be filed to fight off claims it failed to warn women that talcum powder could cause ovarian cancer.
June 20, 2017
Texas becoming big player in life science and biotech industry
Texas is headed to San Diego this week to showcase the state’s thriving biotechnology and life sciences sector at the world’s largest biotechnology conference, BIO International. More than 16,000 biotechnology and pharmaceutical leaders are expected to attend the annual conference, said Texas Economic Development Corporation.
June 19, 2017
Health Canada approves Horizon Pharma’s nephropathic cystinosis drug
Health Canada has issued a Notice of Compliance (NOC) for Horizon Pharma’s Procysbi (cysteamine delayed-release capsules) for the treatment of nephropathic cystinosis in adults and children 2 years of age and older.
June 9, 2017
IDF and Eli Lilly announce second phase of BRIDGES programme funding for translational research in diabetes
International Diabetes Federation (IDF) and Eli Lilly have come together for the second phase of the Bringing Research in Diabetes to Global Environments and Systems programme (BRIDGES 2), reaffirming their commitment to helping people with diabetes effectively manage their condition.
June 9, 2017
FDA approves first generic of drug for prevention of HIV and to treat HIV-1
The U.S. Food and Drug Administration has approved the first generic version of Gilead’s Truvada for the treatment of HIV-1, in combination with other antiretroviral agents, and for pre-exposure prophylaxis (PrEP) in combination with safer sex practices to prevent sexually-acquired HIV infection in adults at high risk.
June 9, 2017
J&J receives final EC approval to acquire Actelion
Johnson & Johnson has announced that, with today’s receipt of approval of the proposed acquisition of Actelion from the European Commission (EC), all regulatory approvals required to complete the transaction have been received.
June 7, 2017
Grünenthal buys AstraZeneca’s migraines drug
AstraZeneca has signed an agreement with Grünenthal for the global rights to Zomig (zolmitriptan), the drug indicated for the acute treatment of migraines and cluster headaches, outside Japan.
June 6, 2017
BMS and Novartis join forces to fight cancer
Bristol-Myers Squibb and Novartis have entered into a clinical research collaboration to investigate the safety, tolerability and efficacy of Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen in combination with Mekinist (trametinib), as a potential treatment option for metastatic colorectal cancer in patients with microsatellite stable tumors where the tumors are proficient in mismatch repair (MSS mCRC pMMR).
June 6, 2017
FDA OK’s Alkermes’s schizophrenia drug
The U.S. Food and Drug Administration (FDA) has approved Alkermes’s two-month Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia.